Holly Lindgren

Holly Lindgren, a Principal Associate Scientist at Alnylam Pharmaceuticals, has a strong background in developing and optimizing ELISAs to detect protein expression in animal tissues. With experience at various companies such as Voyager Therapeutics, Genzyme, and Biogen Idec Hemophelia, Holly has worked on a variety of projects ranging from clinical specialty lab testing to in vivo hemophilia studies. Holly's expertise also includes developing assays for clinical research and optimizing testing procedures for faster and more consistent analysis. Holly holds a Bachelor of Science in Biological Sciences from the University of Massachusetts Lowell and continues to expand their knowledge at Harvard Extension School.